57 completed, 8 terminated, 2 unknown, 2 withdrawn. 18 Phase 3, 17 Phase 1, 15 Phase 4, 14 Phase 2, 6 Not applicable.
Follow Atazanavir: new trials by email Literature Review of Atazanavir trials Research Report on Atazanavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions Atazanavir, Cobicistat, Atazanavir/Cobicistat Mini-tablet - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 42 | 2022-05-13 | 2022-10-31 |
| Antiviral Agents Against COVID-19 Infection Atazanavir, Daclatasvir 60 mg, Sofusbuvir + Daclastavir 60 mg - COVID-19 | Phase 2 / Phase 3 | Completed | Hospital do Coracao | 256 | 2021-02-15 | 2024-03-22 |
| Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials Belinostat, Atazanavir - Solid Tumor, Hematological Malignancies | Phase 1 | Completed | Acrotech Biopharma Inc. | 8 | 2019-08-05 | 2023-05-03 |
| Population Pharmacokinetics of Antiretroviral in Children Dolutegravir, Raltegravir, Rilpivirine - Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed | Completed | Assistance Publique - Hôpitaux de Paris | 65 | 2017-06-16 | 2026-04-03 | |
| A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat Daclatasvir, Atazanavir, Ritonavir - Hepatitis C, HIV | Phase 1 | Completed | Radboud University Medical Center | 16 | 2015-11-01 | 2020-12-07 |
| Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen Atazanavir, Dolutegravir, Lamivudine - HIV-1 Infection | Phase 2 | Terminated | Radboud University Medical Center | 9 | 2015-08-01 | 2020-12-07 |
| Taste Properties of Atazanavir and Cobicistat Atazanavir, Cobicistat, Active Pharmaceutical Ingredient - HIV in Adults | Phase 1 | Completed | Bristol-Myers Squibb | 6 | 2014-12-12 | 2022-01-05 |
| Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Raltegravir (MK-0518), Nevirapine, Lamivudine - HIV Infections | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 11 | 2014-09-03 | 2019-04-08 |
| A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir - Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | Completed | ViiV Healthcare | 499 | 2013-08-22 | 2024-02-20 |
| Study to Evaluate a HIV Drug for the Treatment of HIV Infection BMS-955176, Placebo matching with BMS-955176, Atazanavir - Infection, Human Immunodeficiency Virus, HIV Infections | Phase 2 | Completed | ViiV Healthcare | 107 | 2013-04-04 | 2019-11-25 |
| Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC - Human Immunodeficiency Virus Type 1 (HIV-1) | Phase 1 | Completed | Bristol-Myers Squibb | 64 | 2013-04-01 | 2014-08-29 |
| Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients Atazanavir, Ritonavir - HIV, Pediatric | Phase 4 | Completed | Bristol-Myers Squibb | 108 | 2012-11-30 | 2018-04-27 |
| Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC Atazanavir, Ritonavir, Lamivudine - HIV | Phase 3 | Terminated | Bristol-Myers Squibb | 3 | 2012-07-31 | 2024-01-10 |
| Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone Atazanavir, Darunavir, Ritonavir - HIV | Phase 3 | Withdrawn | Bristol-Myers Squibb | 2012-06-30 | 2023-12-19 | |
| MARCH Central Nervous System Substudy Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors, Arm 2 Maraviroc and Protease Inhibitors, Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors - HIV-1 Infection | Completed | Kirby Institute | 28 | 2012-06-01 | 2016-01-20 | |
| MARCH Renal Substudy arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors, Arm 2 boosted protease inhibitors and maraviroc, Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc - Proteinuria, HIV | Phase 4 | Completed | Kirby Institute | 76 | 2012-06-01 | 2016-01-20 |
| A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir atazanavir, danoprevir, ritonavir - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 40 | 2012-05-01 | 2016-11-02 |
| A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus Atazanavir - Type 1 Diabetes Mellitus | Phase 1 | Completed | Brigham and Women's Hospital | 15 | 2012-05-01 | 2014-07-21 |
| A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir Lopinavir, Atazanavir - HIV | Phase 3 | Withdrawn | ANRS, Emerging Infectious Diseases | 2012-03-01 | 2012-11-08 | |
| Atazanavir and Endothelial Function in Older HIV Patients Atazanavir, Placebo - HIV | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 60 | 2011-12-01 | 2017-05-16 |
Showing 20 of 69. Sign in to see all of them.
HIV Infections (38) · Acquired Immunodeficiency Syndrome (8) · Infections (3) · Hyperlipidemias (2) · Atherosclerosis (1) · COVID-19 (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Dyslipidemias (1) · Endotoxemia (1) · Hematologic Neoplasms (1) · Hepatitis C (1) · Hypersensitivity (1) · Inflammation (1) · Proteinuria (1)
Bristol-Myers Squibb (20) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (4) · Radboud University Medical Center (4) · Boehringer Ingelheim (3) · Brigham and Women's Hospital (2) · French National Agency for Research on AIDS and Viral Hepatitis (2) · Hoffmann-La Roche (2) · Kirby Institute (2) · ViiV Healthcare (2) · ANRS, Emerging Infectious Diseases (1) · Acrotech Biopharma Inc. (1) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Foundation for Cardiovascular Research, Zurich (1)
United States (43) · France (13) · Puerto Rico (11) · Argentina (10) · Canada (10) · Germany (10) · Italy (10) · Thailand (10) · Mexico (9) · United Kingdom (9) · Brazil (8) · South Africa (8) · Spain (8) · Netherlands (7) · Peru (6)
Alan Winston, MD (1) · Alexandra Calmy (1) · Andrew R Zolopa (1) · Bonaventura Clotet, MD, PhD (1) · Cecilia Shikuma, MD (1) · Christophe Piketty, MD (1) · Constance Benson (1) · David Burger (1) · David Burger, PharmD, PhD (1)
PMID 24979445, PMID 33901188, PMID 25904376, PMID 26797215, PMID 32829410, PMID 35179037, PMID 38160309, PMID 14669723, PMID 15115831, PMID 15155205, PMID 15199325, PMID 16287792, PMID 16905783, PMID 16905786, PMID 17310819, PMID 17357053, PMID 17576825, PMID 18193496, PMID 18636958, PMID 18653575, PMID 19118378, PMID 19191590, PMID 19358725, PMID 19710077, PMID 19906626, PMID 19952143, PMID 19952712, PMID 20102271, PMID 20121419, PMID 20961784, PMID 21148235, PMID 21148251, PMID 21320923, PMID 21470045, PMID 21499794, PMID 21555816, PMID 21606537, PMID 21628668, PMID 21690627, PMID 21732894, PMID 21767103, PMID 22121190, PMID 22394315, PMID 22585772, PMID 22592092, PMID 22936892, PMID 23148287, PMID 23196938, PMID 23204164, PMID 23459496
U01AI068636 (4), 2009 (3), K24AI051966 (2), 2004 (1), 2005 (1), K23AI074390 (1), R01HL072711 (1), R03AI068438 (1)